NCT03060070View on ClinicalTrials.gov

Ketamine Versus Dexmedetomidine With Local Anesthetic in TAP Block

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 10, 2017

Primary Completion Date

June 25, 2017

Study Completion Date

July 1, 2017

Conditions
Postoperative AnalgesiaLower Abdominal Cancer
Interventions
DRUG

Ketamine

Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block

DRUG

dexmedetomidine

dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block

DRUG

control group

20ml of 0.25% bupivacaine will be injected in each side of the TAP block

Trial Locations (1)

171516

South Egypt Cancer Institute, Asyut

All Listed Sponsors
collaborator

South Egypt Cancer Institute

OTHER

lead

Assiut University

OTHER

NCT03060070 - Ketamine Versus Dexmedetomidine With Local Anesthetic in TAP Block | Biotech Hunter | Biotech Hunter